Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
- Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol can be given in a metered dose inhaler (MDI) or with a nebulizer. Researchers want to compare these methods to see which method best improves lung function in women with LAM.
- To see whether a nebulizer or MDI can better improve lung function in women with LAM.
- Women at least 18 years of age who have impaired lung function because of LAM.
- Participants will be screened with a physical exam and medical history. No lab tests will be needed for this study.
- Participants will have a 3-day overnight stay at the National Institutes of Health. Those who are using long-acting inhalers will have to stop taking these drugs 1 week before the study.
- Participants will receive either the nebulizer or two or four puffs of the inhaler. Four puffs of albuterol is a higher dose than is normally prescribed, and is being tested on this study.
- Participants will have each treatment around the same time of day on each of the 3 days. Before and after taking the albuterol, participants will have lung function tests.
|Lymphangioleiomyomatosis||Drug: albuterol inhaler Procedure: PFT Drug: albuterol nebulizer||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||Bronchodilator Effects of Nebulized Versus Inhaled Albuterol In Subjects With Lymphangioleiomyomatosis|
- Greater improvement in lung function with nebulized albuterol. [ Time Frame: 3 days ]
|Study Start Date:||December 18, 2012|
|Estimated Study Completion Date:||November 1, 2017|
|Estimated Primary Completion Date:||October 1, 2017 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01799538
|Contact: Tania R Machado||(301) email@example.com|
|Contact: Angelo M Taveira-DaSilva, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Angelo M Taveira-DaSilva, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|